Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study

Andersen, Anne Sofie Schott; Maarbjerg, Stine; Noory, Navid; Heinskou, Tone Bruvik; Forman, Julie Lyng; Cruccu, G.; Ashina, Messoud; Bendtsen, Lars

doi:10.1016/s1474-4422(22)00294-0

Cited by 16 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Andersen reported in 2022 the first randomized, double-blind, placebo-controlled trial to evaluate the effect of erenumab in patients with TN [ 10 ]. The study suggested that erenumab is ineffective in reducing both pain intensity and the frequency of pain paroxysms in TN compared with a placebo.…”

Section: Discussionmentioning

confidence: 99%

“…Previously, two reports described the efficacy of erenumab for TN [9,10], but similar articles remain few.…”

Section: Introductionmentioning

confidence: 99%

“…Calcitonin gene-related peptide (CGRP) is a crucial peptide in the pathophysiology of orofacial pain. In TN and migraine patients, CGRP is increased [ 9 , 10 ]. It is suggested that CGRP generated from intraganglionic areas may affect pain transmission by releasing different cytokines because CGRP is also high in TN patients.…”

Section: Introductionmentioning

confidence: 99%

“…Previously, two reports described the efficacy of erenumab for TN [ 9 , 10 ], but similar articles remain few. Here, we report six cases of comorbid TN in patients with migraine as real-world data and an early experience.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine

Katsuki¹,

Kawamura²,

Kashiwagi³

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundSurgical treatment for trigeminal neuralgia (TN) sometimes becomes difficult. Erenumab, an anti-calcitonin gene-related peptide (CGRP)-receptor monoclonal antibody, is used for migraine and potentially has efficacy for TN. MethodWe retrospectively investigated six migraine patients with comorbidity treated with 70 mg of erenumab. Monthly headache days and a numerical rating scale (NRS) of TN were evaluated before, one, and three months after erenumab administration. ResultsBefore being treated with 70 mg of erenumab, the six migraine patients with comorbid TN had taken at least one sort of preventative medication, but it had been ineffective. During the three-month erenumab use, previous medications were continued. The median age was 71 years (range 59-87). The six patients (five females and one male) had episodic migraine. Three had TN due to vessels, one had TN due to a tumor, one had TN without neurovascular compression, and one had an undetermined etiology. Five (83%) of the six patients reported improved NRS of TN. The median NRS of TN before, one, and three months after treatment were 8 (7-10), 3.5 (0-10), and 2 (0-5, n=4). Monthly headache days were 4 (4-10), 2.5 (0-4), and 1 (1-2, n=4). There were no side effects of erenumab. ConclusionSurgical treatment sometimes cannot be performed for those with TN. Our findings were preliminary and a bigger sample size is required for this study to draw firmer conclusions. However, it is possible, although rare, that there are migraine patients for whom the NRS of comorbid TN improves with the use of erenumab, an anti-CGRP receptor monoclonal antibody.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Previously, two reports described the efficacy of erenumab for TN [9,10], but similar articles remain few.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine

Katsuki¹,

Kawamura²,

Kashiwagi³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Palmatine Inhibiting the expression of CGRP and its receptors Trigeminal neuralgia [77] Tetramethylpyrazine Decrease in expression level of CGRP Trigeminal neuralgia [78] Emodin CGRP was significantly decreased Trigeminal neuralgia [79] Xiongmatang CGRP positive expression, mRNA expression, and protein expression reduction Migraine [80] Botulinum toxin type A CGRP levels decrease significantly Trigeminal neuralgia [81] MK-8825 CGRP receptor blocking Trigeminal neuropathic pain [83] Monoclonal anti-CGRP antibody (Sigma) Decreased with the anti-CGRP antibody The infraorbital nerve ligation modelc [84] Rimegepant CGRP receptor blocking Migraine [85] Galcanezumab CGRP monoclonal antibody SUNCT [86] Monoclonal anti-CGRP antibody (Sigma) Anti-CGRP antibody Trigeminal neuropathic pain [87] Erenumab CGRP receptor monoclonal antibody Trigeminal neuralgia [88] Erenumab CGRP receptor monoclonal antibody Trigeminal neuralgia [89] Erenumab CGRP receptor monoclonal antibody Trigeminal neuralgia [90] Galcanezumab/Fremanezumab CGRP monoclonal antibody Migrainec [91] Fremanezumab CGRP monoclonal antibody Chronic migraine [92] FKBP51 CGRP decrease CRS-induced corneal hyperalgesia [95] Resiniferatoxin Loss of CGRP immunoreactivity Capsaicin eye wipe [96] Abbreviations: CGRP, calcitonin gene-related peptide; CRS, chronic restraint stress; FKBP51, FK506-binding protein 5; SUNCT, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing.…”

Section: Drug the Level Of Cgrp Disease [References]mentioning

confidence: 99%

Calcitonin gene‐related peptide and persistent corneal pain: A trigeminal nerve sensitization perspective

Hong,

Ding,

Xiong

et al. 2023

Brain-X

View full text Add to dashboard Cite

Persistent corneal pain (PCP) has excellent research prospects, especially the central sensitization mechanism of the trigeminal nerve, which is involved in migraine, corneal pain, and trigeminal neuralgia. The cornea has dense sensory innervation, and repeated corneal neuropathic pain has been associated with trigeminal nerve central sensitization, which is induced in PCP. The calcitonin gene‐related peptide (CGRP) is involved in corneal pain conduction, injury protection, and immune homeostasis. A high CGRP level maintains corneal pain perception and protects corneal epithelial cells. However, a persistently high CGRP level causes hypersensitivity of the corneal and trigeminal nerves, resulting in PCP. CGRP‐related drugs can effectively improve trigeminal nerve sensitization and relieve central sensitization‐related pain (PCP, migraine, and trigeminal neuralgia). Exploring the role of CGRP in PCP's pain sensitization mechanism is vital in the pain perception field, with the potential to improve the quality of life of patients with PCP and strengthen the understanding of CGRP's dual role in corneal pain.

show abstract

A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders

Baron,

Steenerson

2024

Curr Treat Options Neurol

View full text Add to dashboard Cite

Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study

Cited by 16 publications

References 36 publications

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine

Calcitonin gene‐related peptide and persistent corneal pain: A trigeminal nerve sensitization perspective

A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders

Contact Info

Product

Resources

About